These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23974795)

  • 1. Ursodeoxycholyl lysophosphatidylethanolamide inhibits lipoapoptosis by shifting fatty acid pools toward monosaturated and polyunsaturated fatty acids in mouse hepatocytes.
    Chamulitrat W; Liebisch G; Xu W; Gan-Schreier H; Pathil A; Schmitz G; Stremmel W
    Mol Pharmacol; 2013 Nov; 84(5):696-709. PubMed ID: 23974795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
    Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
    Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
    Pathil A; Mueller J; Warth A; Chamulitrat W; Stremmel W
    Hepatology; 2012 May; 55(5):1369-78. PubMed ID: 22183915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent.
    Chamulitrat W; Burhenne J; Rehlen T; Pathil A; Stremmel W
    Hepatology; 2009 Jul; 50(1):143-54. PubMed ID: 19496180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursodeoxycholyl lysophosphatidylethanolamide protects against hepatic ischemia and reperfusion injury in mice.
    Wang J; Deng X; Yi S; Pathil A; Zhang W; Setchell K; Stremmel W; Chamulitrat W
    Shock; 2015 Apr; 43(4):379-86. PubMed ID: 25526375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The synthetic bile acid-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide suppresses TNFα-induced liver injury.
    Pathil A; Warth A; Chamulitrat W; Stremmel W
    J Hepatol; 2011 Apr; 54(4):674-84. PubMed ID: 21146893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ursodeoxycholyl lysophosphatidylethanolamide protects against hepatic ischemia/reperfusion injury via phospholipid metabolism-mediated mitochondrial quality control.
    Gu J; Zhang T; Guo J; Chen K; Wang G; Li H; Wang J
    FASEB J; 2020 May; 34(5):6198-6214. PubMed ID: 32162746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of different bile acid-phospholipid conjugates in acute hepatitis.
    Pathil A; Warth A; Chamulitrat W; Stremmel W
    Eur J Clin Invest; 2012 Feb; 42(2):130-8. PubMed ID: 21707612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-inflammatory properties of ursodeoxycholyl lysophosphatidylethanolamide in endotoxin-mediated inflammatory liver injury.
    Ludwig JM; Zhang Y; Chamulitrat W; Stremmel W; Pathil A
    PLoS One; 2018; 13(5):e0197836. PubMed ID: 29795632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Bile Acid-Phospholipid Conjugate Ursodeoxycholyl-Lysophosphatidylethanolamide (UDCA-LPE) Disintegrates the Lipid Backbone of Raft Plasma Membrane Domains by the Removal of the Membrane Phospholipase A2.
    Stremmel W; Staffer S; Fricker G; Weiskirchen R
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholyl Lysophosphatidylethanolamide Protects Against CD95/FAS-Induced Fulminant Hepatitis.
    Utaipan T; Otto AC; Gan-Schreier H; Chunglok W; Pathil A; Stremmel W; Chamulitrat W
    Shock; 2017 Aug; 48(2):251-259. PubMed ID: 28060213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma membrane phospholipase A2 controls hepatocellular fatty acid uptake and is responsive to pharmacological modulation: implications for nonalcoholic steatohepatitis.
    Stremmel W; Staffer S; Wannhoff A; Pathil A; Chamulitrat W
    FASEB J; 2014 Jul; 28(7):3159-70. PubMed ID: 24719358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatoprotectant ursodeoxycholyl lysophosphatidylethanolamide increasing phosphatidylcholine levels as a potential therapy of acute liver injury.
    Chamulitrat W; Zhang W; Xu W; Pathil A; Setchell K; Stremmel W
    Front Physiol; 2012; 3():24. PubMed ID: 22363296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursodeoxycholyl lysophosphatidylethanolamide negatively regulates TLR-mediated lipopolysaccharide response in human THP-1-derived macrophages.
    Horvatova A; Utaipan T; Otto AC; Zhang Y; Gan-Schreier H; Pavek P; Pathil A; Stremmel W; Chamulitrat W
    Eur J Pharmacol; 2018 Apr; 825():63-74. PubMed ID: 29475064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bivalent Ligand UDCA-LPE Inhibits Pro-Fibrogenic Integrin Signalling by Inducing Lipid Raft-Mediated Internalization.
    Su J; Gan-Schreier H; Goeppert B; Chamulitrat W; Stremmel W; Pathil A
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new hypotensive polyunsaturated fatty acid dietary combination regulates oleic acid accumulation by suppression of stearoyl CoA desaturase 1 gene expression in the SHR model of genetic hypertension.
    Bellenger J; Bellenger S; Clément L; Mandard S; Diot C; Poisson JP; Narce M
    FASEB J; 2004 Apr; 18(6):773-5. PubMed ID: 14977874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholyl lysophosphatidylethanolamide inhibits cholestasis- and hypoxia-induced apoptosis by upregulating antiapoptosis proteins.
    Sellinger M; Xu W; Pathil A; Stremmel W; Chamulitrat W
    Exp Biol Med (Maywood); 2015 Feb; 240(2):252-60. PubMed ID: 25125499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease.
    Castro RE; Ferreira DM; Afonso MB; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM
    J Hepatol; 2013 Jan; 58(1):119-25. PubMed ID: 22902550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes.
    Azzaroli F; Mehal W; Soroka CJ; Wang L; Lee J; Crispe IN; Boyer JL
    Hepatology; 2002 Jul; 36(1):49-54. PubMed ID: 12085348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of lipoapoptosis and metformin protection in GLP-1 secreting cells.
    Kappe C; Holst JJ; Zhang Q; Sjöholm A
    Biochem Biophys Res Commun; 2012 Oct; 427(1):91-5. PubMed ID: 22982676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.